UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety.

Sofía Lj PeetersMaarten J DeenenAnna Mj ThijsEmma C Hulshof Ron H J Mathijssen André B P van Kuilenburg Henk-Jan Guchelaar Jesse Joachim Swen

Published in: Pharmacogenomics (2023)

Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care.

Keyphrases

patient safety
quality improvement
healthcare
palliative care
clinical practice
primary care
high throughput
high intensity
gene expression
pain management
genetic diversity
smoking cessation
health insurance
affordable care act